[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617246":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":51,"collaborators":25,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","SHAM_COMPARATOR","Participants in the placebo group will receive six sessions of sham treament, each lasting 2.5 hours over two weeks. The procedure will be performed without an adsorption column, allowing the blood to circulate through the extracorporeal circuit and be returned to the patient without removal of immunoglobulins or other plasma components.",[13],"Device: Sham Comparator",{"label":15,"type":16,"description":17,"interventionNames":18},"Immunoadsorption","ACTIVE_COMPARATOR","Participants in the intervention group will receive six sessions of immunoadsorption, each lasting 2.5 hours over two weeks. Immunoadsorption will be performed using tryptophan columns, which bind the Fc region of IgG via hydrophobic and aromatic interactions.",[19],"Device: Immunoadsorption",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Immunoadsorption will be performed using tryptophan columns, which bind the Fc region of IgG via hydrophobic and aromatic interactions.",[15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Sham Comparator","The immunoadsorption column will be removed from the device, so that the patient's blood passes through the system and is returned to the body without undergoing adsorption or removal of antibodies.",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Daphne Schouten, MD","CONTACT","+31 20 566 9111","postcovidtrials@amsterdamumc.nl",[37],{"facility":38,"status":39,"city":40,"state":25,"zip":25,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"AUMC","RECRUITING","Amsterdam","Netherlands","NL",{"type":44,"coordinates":45},"Point",[46,47],4.88969,52.37403,{"lat":47,"lon":46},[50],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","W. J. Wiersinga, MD","Prof. Dr.","100617246","phase-2-immunoadsorption-in-autoimmune-long-covid-100617246",false,"NCT07316127","Immunoadsorption in Autoimmune Long COVID","A Placebo-Controlled, Double-Blind, Randomized Trial Phase I-II With Immunoadsorption in Autoimmune Long COVID","TURNLongCOVID","Inclusion Criteria:\n\n* Long COVID based on the WHO-criteria\n* PEM according to the DSQ-PEM\n* BELL's functionality score 20-70%\n* Good health prior to the long COVID diagnosis (WHO performance score 0)\n\nExclusion Criteria:\n\n* Medical history of clinically significant respiratory- or cardiovascular disease\n* Prior interventional cardiac procedure within 3 months prior to randomization\n* Active immunosuppresive treatment for systemic autoimmune disorders\n* Diabetes type 1\n* Solid organ malignancy in the last 5 years\n* Active psychiatric disorder currently under treatment by a psychiatrist\n* BMI \\> 35\n* Pre-existing fatigue\n* Poor performance score prior to the long COVID diagnosis (WHO performance \\>0)\n* Pregnancy or breastfeeding","ALL","18 Years","65 Years",{"count":67,"type":68},70,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.\n\nThis study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly assigned to receive either the real treatment or a placebo. The main goal is to see whether fatigue improves after one month, and whether other symptoms and daily functioning improve over six months.\n\nThis research will help us find out if this treatment can benefit the group of long COVID patients with immune-related disease.",[74,75,76,77],"Long COVID","Long COVID Syndrome","Long COVID-19 Syndrome","Post COVID Syndrome",[79,80,81,82],"immunoadsorption","long COVID","post COVID","plasmapheresis","2025-12-18",{"date":85,"type":86},"2026-01-05","ACTUAL",{"date":88,"type":68},"2026-01-01",{"date":90,"type":68},"2028-03-12",{"name":5,"class":6},1]